Slide 2:
District Pandemic Vaccine Preparedness Plan – Suggested Contents
Slide 3:
Objectives
To protect those most at risk of infection with pandemic influenza A H1N1 virus.
To prioritize and vaccinate health care workers to ensure that the health facilities providing medical care / H1N1 care are able to continue its operations.
Slide 5:
Demographic Details
Name of district
Total population
Number of health facilities involved in H1N1 care
Government
Private
Target Population
Total
Male
Female
Slide 10:
PANENZA-Pandemic Vaccine
Panenza is a split virus inactivated, non-adjuvanted monovalent vaccine The active ingredient is:
Split Influenza virus*, inactivated, containing antigen equivalent to:
A/California/7/2009 (H1N1)v-like strain (NYMC X-179A) ..............15 micrograms** per 0.5 ml dose
* propagated in eggs ** expressed in microgram haemagglutinin
The other ingredients are: thiomersal (45 micrograms per 0.5 ml dose), sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium dihydrogen phosphate, and water.
PANENZA is a suspension for injection in a multidose vial (10 doses of 0.5ml) - Pack of 10 vials. The suspension is a colourless liquid, clear to opalescent.
Vaccine administration: One dose (0.5 ml) intra muscular [for the defined target group as defined in the objective]
Slide 12:
H1N1 Vaccination Tally Sheet
Slide 13:
H1N1 Reporting Sheet
List of Vaccinators and Supervisors :
List of Vaccinators and Supervisors
AEFI Committee :
AEFI Committee
Slide 16:
--.--.2010 1st State Coordination Committee Meeting TIME LINE OF ACTIVITIES : H1N1 Vaccination Mar / Apr 2010 --.--.2010 District level Procurement of vaccine logistics formats H1N1 Vaccination Dates
– --- , ---Mar / --, ----Apr 2010 --.--.2010 Procurement of Vaccine --.--.2010 Vaccinators & Supervisors Training. --.--.2010 Microplan Submission to State --.--.2010 2nd State Coordination Committee Meeting --.--.2010 :State level DHOs meeting --.--.2010 District Coordination Committee Meeting Planning Cycle